Filing Details
REGENXBIO Inc. (NASDAQ:RGNX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:RGNX
REGENXBIO Inc. (RGNX) Files Quarterly Report for Q0
REGENXBIO Inc. (NASDAQ:RGNX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
At publication ·
What changed
REGENXBIO Inc. (NASDAQ:RGNX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- REGENXBIO Inc. filed its quarterly report (Form 10-Q) with the SEC on November 05, 2026.
- The company's stock trades at $7.71 with a market capitalization of $651.0 million.
- The 10-Q contains unaudited financial statements and management commentary on business performance and emerging trends.
Market Context
REGENXBIO Inc.'s stock currently trades at $7.71 with a market capitalization of $651.0M.
The 10-Q provides REGENXBIO Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for REGENXBIO Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View RGNX Stock Page
Frequently Asked Questions
Where can I read RGNX's SEC filings?
Browse all filings on our RGNX SEC filings page.
What types of SEC filings does REGENXBIO Inc. file?
Public companies like REGENXBIO Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.